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OBJECTIVE—Variants downstream of the melanocortin-4
receptor gene (MC4R) have been reported to associate with
obesity. We examined rs17782313, rs17700633, rs12970134,
rs477181, rs502933, and rs4450508 near MC4R for association
with obesity-related quantitative traits, obesity, and type 2
diabetes in Danish individuals.
RESEARCH DESIGN AND METHODS—The variants were
investigated for association with obesity-related quantitative
traits in 5,807 population-based sampled individuals, obesity
in 14,940 individuals, and type 2 diabetes in 8,821 individuals.
RESULTS—The minor risk alleles of rs17782313, rs17700633,
and rs12970134 were associated with BMI (effect per allele 0.25
kg/m2, P  0.01; 0.23, P  0.01; and 0.31, P  7  104,
respectively), waist circumference (0.67 cm, P  0.006; 0.53, P 
0.02; and 0.85, P  3  104), and body weight (1.04 kg, P  6 
104; 0.71, P  0.01; and 1.16, P  8  105). In case-control
studies of obesity defined by BMI, the minor C-allele of
rs17782313 was associated with overweight/obesity and obesity
(odds ratio [OR] 1.09, P  0.006 and OR 1.12, P  0.003,
respectively). Similarly, the minor A-allele of rs17700633 was
associated with overweight/obesity and obesity (1.12, P  8 
105 and 1.16, P  2  105), and the minor A-allele of
rs12970134 was also associated with overweight/obesity and
obesity (1.13, P  2  105 and 1.15, P  6  105). rs477181,
rs502933, and rs4450508 were not significantly associated with
obesity in the Danish population. The frequency of the minor
risk alleles of rs17782313 and rs12970134 was higher among
patients with type 2 diabetes than among glucose-tolerant
individuals (OR 1.08, P  0.08 and 1.08, P  0.06, respec-
tively); however, these borderline associations were abolished
after adjustment for BMI.
CONCLUSIONS—rs17782313, rs17700633, and rs12970134 near
MC4R associate with measures of obesity in Danish individuals.
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Obesity and the accompanying risk of commondiseases such as type 2 diabetes and prematurecardiovascular morbidity and mortality are in-creasing global health burdens. Multiple varia-
tions in genes are likely to contribute to the pathogenesis
of obesity. Monogenic forms of obesity have been identi-
fied, with mutations in the gene encoding the melanocor-
tin-4 receptor (MC4R) being the most prevalent (1–3).
MC4R is located on chromosome 18q22 (4) and expressed
in the central nervous system (5) where the encoded
protein is involved in appetite regulation (6). Variation in
MC4R has been reported to associate with common forms
of obesity (7–9). Variation in the fat mass and obesity-
associated gene (FTO) was the first example of common
genetic variation for which there is widely replicated
evidence of association with obesity in the general popu-
lation (10–12). Recently, in a study analyzing genome-wide
association data from white Europeans informative for
BMI, variation in FTO was also found with the strongest
BMI-association signal, followed by signals mapping to
chromosome 18q21, 188 kb (rs17782313), and 109 kb
(rs17700633) downstream of MC4R (13). Case-control
studies confirmed associations of rs17782313 and
rs17700633 with obesity, and a separate analysis identified
a relationship between rs17782313 and morbid obesity
(13). Low pairwise linkage disequilibrium was found be-
tween the two variants (r2  0.10 in CEU HapMap). An
independent genome-wide association study performed
in Indian people identified four variants (rs12970134,
rs477181, rs502933, and rs4450508) in high linkage disequi-
librium (0.57–1.0 in CEU HapMap) 150 kb downstream
of MC4R associated with increased waist circumference,
body weight, waist-to-hip ratio, and insulin resistance, of
which the most strongly associated variant (rs12970134)
(14) was in high linkage disequilibrium with rs17782313
(0.81 in CEU HapMap).
The aim of the present study was to examine the
influence of rs17782313, rs17700633, rs12970134, rs477181,
rs502933, and rs4450508 near MC4R on obesity-related
quantitative traits in the general population of middle-aged
people and to validate previously published associations
of the variants with obesity (13,14) in the Danish popula-
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TABLE 1
Unadjusted anthropometric and metabolic characteristics of 5,807 treatment-naïve unrelated individuals from the population-based
Inter99 sample stratified according to genotype of rs17782313, rs17700633, rs12970134, rs502933, or rs4450508 near MC4R
Genotype P Effect per allele
rs17782313 T/T T/C C/C
n (men/women) 3,291 (1,657/1,634) 2,159 (1,059/1,100) 357 (165/192)
Age (years) 46 8 46 8 46 8
BMI (kg/m2) 26.1 4.5 26.4 4.5 26.4 4.7 0.01* 0.25 (0.06–0.43)
Weight (kg) 77.6 15.9 78.7 15.9 78.7 17.1 6  104* 1.04 (0.45–1.64)
Waist (cm) 86 13 87 13 87 14 0.006* 0.67 (0.19–1.15)
Waist-to-hip ratio 0.85 0.09 0.86 0.09 0.85 0.09 0.20
Height (cm) 172.2 9.3 172.4 9.1 172.2 8.9 0.02* 0.33 (0.06–0.61)
Fasting
Plasma glucose (mmol/l) 5.5 0.8 5.6 0.8 5.5 0.6 0.82
Serum insulin (pmol/l) 42 28 43 28 39 25 0.50
Serum C-peptide (pmol/l) 591 269 608 282 576 257 0.80
Serum triglycerides (mmol/l) 1.3 1.6 1.3 1.1 1.3 0.8 0.80
Serum total cholesterol (mmol/l) 5.5 1.1 5.5 1.1 5.5 1.0 0.23
Serum HDL cholesterol (mmol/l) 1.4 0.4 1.4 0.4 1.5 0.4 0.42
HOMA-IR (pmol/l  mmol/l) 10.5 8.2 10.8 7.9 9.9  6.7 0.53
rs17700633 G/G G/A A/A
n (men/women) 2,753 (1,376/1,377) 2,520 (1,255/1,265) 525 (253/272)
Age (years) 46 8 46 8 46 8
BMI (kg/m2) 26.1 4.6 26.3 4.5 26.6 4.5 0.01* 0.23 (0.05–0.41)
Weight (kg) 77.8 16.2 78.2 15.7 79.3 15.9 0.01* 0.71 (0.15–1.28)
Waist (cm) 86 13 87 13 87 14 0.02* 0.53 (0.07–0.98)
Waist-to-hip ratio 0.85 0.09 0.86 0.09 0.86 0.09 0.10
Height (cm) 172.3 9.4 172.3 9.1 172.5 9.1 0.43
Fasting
Plasma glucose (mmol/l) 5.5 0.8 5.5 0.7 5.6 0.9 0.78
Serum insulin (pmol/l) 42 28 41 28 43 29 0.31
Serum C-peptide (pmol/l) 593 277 596 269 610 272 0.90
Serum triglycerides (mmol/l) 1.3 1.6 1.3 1.1 1.4 1.3 0.37
Serum total cholesterol (mmol/l) 5.5 1.1 5.6 1.1 5.5 1.1 0.81
Serum HDL cholesterol (mmol/l) 1.5 0.4 1.4 0.4 1.4 0.4 0.06
HOMA-IR (pmol/l  mmol/l) 10.7 8.1 10.5 8.0 10.9 7.9 0.33
rs12970134 G/G G/A A/A
n (men/women) 2,982 (1,495/1,487) 2,339 (1,159/1,180) 465 (221/244)
Age (years) 46 8 46 8 46 8
BMI (kg/m2) 26.0 4.5 26.4 4.6 26.5 4.6 7  104* 0.31 (0.13–0.49)
Weight (kg) 77.4 15.9 78.8 16.0 79.0 16.9 8  105* 1.16 (0.58–1.73)
Waist (cm) 86 13 87 13 87 14 3 104* 0.85 (0.39–1.31)
Waist-to-hip ratio 0.85 0.09 0.86 0.09 0.86 0.09 0.01* 0.003 (0.001–0.006)
Height (cm) 172.2 9.3 172.4 9.2 172.3 8.8 0.06
Fasting
Plasma glucose (mmol/l) 5.5 0.8 5.6 0.8 5.5 0.6 0.75
Serum insulin (pmol/l) 42 28 43 28 41 26 0.48
Serum C-peptide (pmol/l) 588 266 609 287 581 252 0.81
Serum triglycerides (mmol/l) 1.3 1.6 1.3 1.1 1.3 0.8 0.99
Serum total cholesterol (mmol/l) 5.6 1.1 5.5 1.1 5.5 1.1 0.11
Serum HDL cholesterol (mmol/l) 1.5 0.4 1.4 0.4 1.4 0.4 0.07
HOMA-IR (pmol/l  mmol/l) 10.5 8.0 10.8 8.2 10.1 7.2 0.45
rs502933 C/C C/A A/A
n (men/women) 2,416 (1,233/1,183) 2,582 (1,273/1,309) 744 (346/398)
Age (years) 46 8 46 8 46 8
BMI (kg/m2) 26.1 4.5 26.3 4.6 26.2 4.4 0.16
Weight (kg) 77.8 15.9 78.4 16.0 78.0 16.3 0.03
Waist (cm) 86 13 87 13 86 13 0.06
Waist-to-hip ratio 0.86 0.09 0.86 0.09 0.86 0.09 0.10
Height (cm) 172.3 9.3 172.3 9.1 172.3 9.0 0.05
Fasting
Plasma glucose (mmol/l) 5.6 0.9 5.6 0.8 5.5 0.7 0.69
Serum insulin (pmol/l) 42 28 43 29 40 25 0.47
Serum C-peptide (pmol/l) 592 272 603 279 585 252 0.85
Serum triglycerides (mmol/l) 1.4 1.7 1.3 1.1 1.3 0.9 0.19
Serum total cholesterol (mmol/l) 5.6 1.1 5.5 1.1 5.5 1.1 0.09
Serum HDL cholesterol (mmol/l) 1.4 0.4 1.4 0.4 1.4 0.4 0.50
HOMA-IR (pmol/l  mmol/l) 10.6 8.2 10.7 8.1 10.0 7.0 0.43
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tion. Finally, a potential association of these obesity-
associated variants with type 2 diabetes was explored.
RESEARCH DESIGN AND METHODS
Case-control studies of obesity were performed in 14,940 Danish individuals
from three study groups: 1) a subgroup of the population-based Inter99
sample (n  5,807) recruited from the Research Centre for Prevention and
Health (ClinicalTrials.gov identifier: NCT00289237; ref. 15); 2) the Danish
subsample of the ADDITION (Anglo-Danish-Dutch Study of Intensive Treat-
ment in People with Screen-Detected Diabetes in Primary Care) screening
cohort (n  8,487) sampled by the Department of General Practice at the
University of Aarhus, Aarhus, Denmark (ClinicalTrials.gov identifier:
NCT00237548; ref. 16); and 3) a population-based group of unrelated middle-
aged individuals (n  646) examined at Steno Diabetes Center (SDC).
Individuals with a previous diagnosis of type 2 diabetes were excluded from
studies of obesity because medication might have affected body weight.
Individuals were defined as lean (BMI 25 kg/m2) or overweight/obese (25
kg/m2). Furthermore, analyses were carried out on subgroups of obese (30
kg/m2) or morbidly obese individuals (40 kg/m2). Individuals were further
stratified according to sex-specific waist circumference: in the latter context,
we defined individuals with a waist circumference 80 cm (women) or 94
cm (men) as lean, overweight/abdominally obese individuals were 80 cm
(women) or 94 cm (men), and a subgroup of abdominally obese individuals
was characterized by waist circumference 88 cm (women) or 102 cm
(men). Conditional analyses of case-control studies on BMI were performed in
the Inter99, ADDITION, and the SDC study samples.
Case-control studies of type 2 diabetes (diagnosed according to the 1999
World Health Organization criteria [17]) were performed in 4,918 glucose-
tolerant individuals and 3,903 case individuals from the above-mentioned
cohorts plus a sample of unrelated type 2 diabetic patients from the outpatient
clinic at SDC (n  1,964). Further details of the study populations are found
in Supplementary Tables A–B (available online at http://diabetes.
diabetesjournals.org/cgi/content/full/db08-0620/DC1).
Studies of obesity-related quantitative traits, physical activity, and additive
effects between rs12970134 near MC4R and FTO rs9939609 and conditional
analyses on BMI as a quantitative trait were performed in the Inter99 cohort
(n 5,807), excluding individuals with a previous diagnosis of type 2 diabetes.
All participants were of self-reported Danish nationality, and informed
written consent was obtained before participation. Studies were approved by
regional ethics committees and were in accordance with the principles of the
Helsinki Declaration II.
Anthropometrical and biochemical measurements. Body weight and
height were measured with individuals wearing light clothing. Waist circum-
ference was measured midway between the iliac crest and the lower costal
margin. Blood samples were taken after an overnight fast of 8 h. Plasma
glucose, serum insulin, C-peptide, and lipids were measured using SDC
standard methods. The level of physical activity was self-reported by ques-
tionnaire (18).
Genotyping. Genotyping of rs17782313, rs17700633, rs12970134, rs477181,
rs502933, and rs4450508 was performed using TaqMan allelic discrimination
(KBioscience, Herts, U.K.). The genotyping success rates were 96%, and
among 721 replicate samples error rates of 0.0%, 0.3%, 0.0%, 0.1%, 0.2%, and
0.1%, respectively, were observed. Genotype distributions obeyed Hardy-
Weinberg equilibrium (P  0.05).
Statistical analyses. For case-control studies, differences in genotype dis-
tributions were calculated applying an additive logistic regression model
adjusted for sex and age. A general linear model tested variables of quantita-
tive traits for differences between genotype groups and was adjusted for sex
and age (and BMI where appropriate). For obesity-related analyses, the
Benjamini-Hochberg method was used separately for each variant to correct
for multiple testing (19). A test for homogeneity between the SDC population-
based sample, Inter99, and the ADDITION cohort was performed for all
variants by means of the Mantel-Haenszel method (fixed-effects model), and it
revealed no heterogeneity between the studies (P 0.64–0.97). Linear models
were used to test for interaction between genotypes and physical activity
on BMI or waist circumference using an ANOVA test. To assess whether
variants affect body composition independently of each other, individual
SNP contributions were analyzed by conditional analysis comparing linear
models including single or pairwise genetic parameters. The combined
effect of rs12970134 and FTO rs9939609 on BMI was assessed assuming
additive effects of each variant (P  0.11; equal effect sizes on BMI could
be assumed for the two variants). Additivity was assessed comparing a
linear model that assumed equal effects between rs12970134 and rs9939609
by summarizing the number of risk alleles as the genetic parameter with a
model without a genetic parameter. Analyses were performed with RGui
(version 2.5.0; R Development for Statistical Computing, Vienna). A P value
0.05 was considered significant.
RESULTS
Six variants near MC4R (rs17782313, rs17700633, rs12970134,
rs502933, rs477181, and rs4450508) were genotyped in the
Danish population, of which rs502933 and rs477181 were
in complete linkage disequilibrium and, therefore, the
results for rs477181 are not shown (pairwise linkage
disequilibrium structure for the six variants are found in
Supplementary Fig. 1). In the population-based Inter99
sample involving 5,807 treatment-naïve, unrelated individ-
uals, rs17782313, rs17700633, and rs12970134 were associ-
TABLE 1
Continued
Genotype P Effect per allele
rs4450508 G/G G/A A/A
n (men/women) 2,324 (1,191/1,133) 2,590 (1,286/1,304) 815 (383/432)
Age (years) 46 8 46 8 46 8
BMI (kg/m2) 26.1 4.5 26.3 4.6 26.1 4.4 0.53
Weight (kg) 77.9 15.8 78.4 16.0 77.8 16.2 0.13
Waist (cm) 87 13 87 13 86 13 0.21
Waist-to-hip ratio 0.86 0.09 0.86 0.09 0.86 0.09 0.17
Height (cm) 172.3 9.4 172.4 9.1 172.3 9.1 0.04
Fasting
Plasma glucose (mmol/l) 5.5 0.8 5.5 0.8 5.5 0.8 0.87
Serum insulin (pmol/l) 42 28 43 29 40 25 0.88
Serum C-peptide (pmol/l) 591 270 602 280 588 258 0.43
Serum triglycerides (mmol/l) 1.4 1.8 1.3 1.0 1.3 1.0 0.34
Serum total cholesterol (mmol/l) 5.6 1.1 5.5 1.1 5.5 1.1 0.08
Serum HDL cholesterol (mmol/l) 1.4 0.4 1.4 0.4 1.4 0.4 0.40
HOMA-IR (pmol/l  mmol/l) 10.6 8.1 10.7 8.2 10.1 7.0 0.91
Data are means  SD (unadjusted) or effect size estimate (95% CI) unless otherwise indicated. Calculated P values and effect size estimates
were adjusted for age and sex for obesity-related quantitative traits and height and for age, sex, and BMI for plasma glucose, serum insulin,
serum C-peptide, serum lipids, and HOMA-IR. Values of plasma glucose, serum insulin, serum C-peptide, serum triglycerides, and HOMA-IR
were logarithmically transformed before statistical analysis. HOMA-IR was calculated as fasting plasma glucose (mmol/l) multiplied by
fasting serum insulin (pmol/l) divided by 22.5. P values were calculated assuming an additive model. *P values remained significant after
Benjamini-Hochberg correction.
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ated with obesity-related quantitative traits of BMI (effect
per minor allele 0.25 kg/m2 [95% CI 0.06–0.43], 0.23
[0.05–0.41], and 0.31 [0.13–0.49], respectively; P  0.01,
0.01, and 7  104, respectively) and waist circumference
(effect per minor allele 0.67 cm [0.19–1.15], 0.53 [0.07–
0.98], and 0.85 [0.39–1.31]; P  0.006, 0.02, and 3  104;
TABLE 2
Genotype distributions, minor allele frequencies, and ORs for rs17782313, rs17700633, rs12970134, rs502933, and rs4450508 near
MC4R among 14,940 individuals stratified according to genotype and BMI subgroup or sex-specific waist circumference subgroup
n (men/women) Genotype
Minor allele
frequency
Additive model
OR P
rs17782313 T/T T/C C/C
BMI
25 kg/m2 4,721 (1,946/2,775) 2,721 (57) 1,722 (37) 278 (6) 24.1 (23.3–25.0)
25 kg/m2 10,219 (5,887/4,332) 5,651 (56) 3,915 (38) 653 (6) 25.5 (24.9–26.1) 1.09 (1.02–1.15) 0.006*
30 kg/m2 3,913 (1,988/1,925) 2,136 (55) 1,507 (38) 270 (7) 26.2 (25.2–27.1) 1.12 (1.04–1.20) 0.003*
40 kg/m2 283 (89/194) 148 (52) 112 (40) 23 (8) 27.9 (24.3–31.8) 1.20 (0.99–1.45) 0.06
Waist
80 (women) or
94 cm (men) 5,374 (2,834/2,540) 3,107 (58) 1,954 (36) 313 (6) 24.0 (23.2–24.8)
80 (women) or
94 cm (men) 9,546 (4,986/4,560) 5,247 (55) 3,681 (38) 618 (7) 25.8 (25.1–26.4) 1.10 (1.03–1.16) 0.002*
88 (women) or
102 cm (men) 5,748 (2,720/3,028) 3,158 (55) 2,213 (38) 377 (7) 25.8 (25.0–26.6) 1.09 (1.02–1.16) 0.009*
rs17700633 G/G G/A A/A
BMI
25 kg/m2 4,697 (1,939/2,758) 2,296 (49) 2,002 (42) 399 (9) 29.8 (28.9–30.7)
25 kg/m2 10,135 (5,842/4,293) 4,685 (46) 4,427 (44) 1,023 (10) 31.9 (31.3–32.6) 1.12 (1.06–1.18) 8 105*
30 kg/m2 3,871 (1,964/1,907) 1,744 (45) 1,707 (44) 420 (11) 32.9 (31.9–34.0) 1.16 (1.08–1.24) 2 105*
40 kg/m2 278 (87/191) 108 (39) 143 (51) 27 (10) 35.4 (31.5–39.6) 1.30 (1.08–1.56) 0.005*
Waist
80 (women) or
94 cm (men) 5,346 (2,824/2,522) 2,575 (48) 2,319 (43) 452 (9) 30.1 (29.3–31.0)
80 (women) or
94 cm (men) 9,467 (4,945/4,522) 4,394 (47) 4,104 (43) 969 (10) 31.9 (31.2–32.6) 1.09 (1.03–1.15) 0.002*
88 (women) or
102 cm (men) 5,684 (2,694/2,990) 2,598 (46) 2,495 (44) 591 (10) 32.3 (31.5–33.2) 1.10 (1.04–1.17) 0.001*
rs12970134 G/G G/A A/A
BMI
25 kg/m2 4,694 (1,934/2,760) 2,511 (54) 1,848 (39) 335 (7) 26.8 (25.9–27.7)
25 kg/m2 10,174 (5,869/4,305) 5,073 (50) 4,276 (42) 825 (8) 29.1 (28.5–29.8) 1.13 (1.07–1.20) 2 105*
30 kg/m2 3,886 (1,979/1,907) 1,922 (49) 1,631 (42) 333 (9) 29.6 (28.5–30.6) 1.15 (1.08–1.23) 6 105*
40 kg/m2 282 (88/194) 130 (46) 126 (45) 26 (9) 31.6 (27.7–35.6) 1.25 (1.04–1.50) 0.02*
Waist
80 (women) or
94 cm (men) 5,333 (2,814/2,519) 2,843 (53) 2,104 (40) 386 (7) 27.0 (26.1–27.8)
80 (women) or
94 cm (men) 9,515 (4,976/4,539) 4,726 (50) 4,016 (42) 773 (8) 29.2 (28.6–29.9) 1.12 (1.06–1.19) 3 105*
88 (women) or
102 cm (men) 5,710 (2,715/2,995) 2,831 (50) 2,412 (42) 467 (8) 29.3 (28.5–30.1) 1.12 (1.05–1.19) 4 104*
rs502933 C/C C/A A/A
BMI
25 kg/m2 4,637 (1,904/2,733) 2,002 (43) 2,067 (45) 568 (12) 34.5 (33.6–35.5)
25 kg/m2 10,075 (5,801/4,274) 4,116 (41) 4,678 (46) 1,281 (13) 35.9 (35.3–36.6) 1.07 (1.02–1.13) 0.01
30 kg/m2 3,851 (1,963/1,888) 1,562 (41) 1,786 (46) 503 (13) 36.3 (35.2–37.3) 1.08 (1.02–1.16) 0.01
40 kg/m2 281 (91/190) 104 (37) 136 (48) 41 (15) 38.8 (34.7–43.0) 1.20 (1.01–1.43) 0.04
Waist
80 (women) or
94 cm (men) 5,275 (2,783/2,492) 2,284 (43) 2,346 (45) 645 (12) 34.5 (33.6–35.4)
80 (women) or
94 cm (men) 9,418 (4,909/4,509) 3,824 (41) 4,393 (47) 1,201 (13) 36.1 (35.4–36.8) 1.08 (1.02–1.13) 0.006*
88 (women) or
102 cm (men) 5,662 (2,688/2,974) 2,281 (40) 2,666 (47) 715 (13) 36.2 (35.3–37.1) 1.07 (1.01–1.13) 0.02
rs4450508 G/G G/A A/A
BMI
 25 kg/m2 4,644 (1,916/2,728) 1,912 (41) 2,100 (45) 632 (14) 36.2 (35.2–37.2)
25 kg/m2 10,145 (5,855/4,290) 3,988 (39) 4,781 (47) 1,376 (14) 37.1 (36.5–37.8) 1.05 (0.99–1.10) 0.08
30 kg/m2 3,873 (1,971/1,902) 1,510 (39) 1,820 (47) 543 (14) 37.5 (36.4–38.6) 1.06 (1.00–1.13) 0.06
40 kg/m2 282 (86/196) 100 (36) 140 (49) 42 (15) 39.7 (35.7–43.9) 1.16 (0.98–1.38) 0.09
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although adjustment for BMI abolished these associations
[data not shown]), and body weight (effect per minor allele
1.04 kg [0.45–1.64], 0.71 [0.15–1.28], and 1.16 [0.58–1.73];
P  6  104, 0.01, and 8  105) (Table 1).
rs17782313 was further positively associated with height
(effect per minor allele 0.33 cm [0.06–0.61]; P  0.02),
whereas only rs12970134 was associated with waist-to-hip
ratio (effect per minor allele 0.003 [0.001–0.006]; P 0.01).
No associations with fasting circulating levels of glucose,
insulin, C-peptide, or lipids or with insulin resistance
(homeostasis model assessment of insulin resistance
[HOMA-IR]) were found for any of the six studied variants
regardless of correction for BMI.
In case-control studies of 14,940 Danes from the Inter99,
ADDITION, and the SDC study, samples dichotomized
according to BMI or waist circumference. rs17782313,
rs17700633, and rs12970134 were associated with obesity
(Table 2; separate analyses in the three study samples are
found in Supplementary Tables C–L). The minor C-allele of
rs17782313 was associated with BMI-defined overweight/
obesity and obesity (odds ratio [OR] 1.09 [95% CI 1.02–
1.15], P  0.006, and 1.12 [1.04–1.20], P  0.003,
respectively); however, the risk allele was only borderline
associated with morbid obesity (1.20 [0.99–1.45]; P 
0.06). Also, the minor A-allele of rs17700633 was associ-
ated with overweight/obesity, obesity, and morbid obesity
(1.12 [1.06–1.18], P  8  105; 1.16 [1.08–1.24], P  2 
105; and 1.30 [1.08–1.56], P  0.005). Likewise, the minor
A-allele of rs12970134 was associated with overweight/
obesity, obesity, and morbid obesity (1.13 [1.07–1.20], P 
2  105; 1.15 [1.08–1.23], P  6  105; and 1.25
[1.04–1.50], P  0.02). The frequencies of the potential
minor risk alleles of rs502933, rs477181, and rs4450508
were higher among overweight/obese and obese sub-
jects than among lean subjects; however, these differ-
ences did not reach statistical significance (Table 2; data
not shown).
Moreover, the C-allele of rs17782313 was associated
with overweight/abdominal obesity and abdominal obe-
sity defined by sex-specific waist circumference (1.10
[1.03–1.16], P  0.002, and 1.09 [1.02–1.16], P  0.009,
respectively). Likewise, the A-allele of rs17700633 was
associated with overweight/abdominal obesity and ab-
dominal obesity (1.09 [1.03–1.15], P  0.002, and 1.10
[1.04–1.17], P  0.001). Also, the A-allele of rs12970134
was associated with overweight/abdominal obesity and
abdominal obesity (1.12 [1.06–1.19], P  3  105, and
1.12 [1.05–1.19], P  4  104). Finally, the minor
A-allele of rs502933 was associated with waist circum-
ference–defined overweight/abdominal obesity (1.08
[1.02–1.13]; P  0.006).
Conditional analyses were performed to differentiate
between the effects on BMI of rs12970134, rs17782313, and
rs17700633. In studies of BMI as a quantitative trait, we
found that the association of rs12970134 remained sig-
nificant after analyses conditional on rs17782313 and
rs17700633, respectively. In contrast, all effects on BMI
of rs17782313 and rs17700633 were abolished when
taking the effect of rs12970134 into account (data not
shown). However, in case-control studies of BMI, both
rs12970134 and rs17700633 had independent effects
(data not shown).
In case-control studies including 4,918 glucose-tolerant
individuals and 3,903 patients with type 2 diabetes, the
frequencies of the minor risk alleles of rs17782313 and
rs12970134 were borderline associated with type 2 diabe-
tes (OR 1.08 [0.99–1.18], P  0.08, and 1.08 [1.00–1.18],
P  0.06, respectively) (Table 3); however, these border-
line associations were abolished after adjustment for BMI
(1.04 [0.94–1.14], P  0.48, and 1.03 [0.93–1.13], P  0.57).
For rs17700633, rs502933, rs477181, rs502933, and
rs4450508, the frequencies of the minor risk alleles were
also higher among patients with type 2 diabetes; however,
these differences did not reach statistical significance
(Table 3; data not shown).
A potential interaction between the six variants’ ge-
notypes (analyzed separately) and self-reported physi-
cal activity on BMI or waist circumference was
investigated in the population-based Inter99 cohort. We
found no impact of genotype on BMI or waist circum-
ference associated with the level of physical activity
(data not shown).
In the population-based Inter99 sample of adults, an
additive effect between rs12970134 near MC4R and FTO
rs9939609 on BMI was found (Fig. 1A and B). The impact
on BMI was 0.43 kg/m2 (95% CI 0.30–0.55) per risk allele
(P  1  1011 for additivity). Comparisons of linear
models showed that the FTO rs9939609 has the largest
effect; however, rs12970134 near MC4R contributed to this
association on top of rs9939609 (Fig. 1A).
DISCUSSION
Population-based studies of obesity-related quantitative
traits in the Danish population confirmed previously iden-
tified associations of rs17782313, rs17700633, and
rs12970134 near MC4R with obesity (13,14). The effect
sizes per minor risk allele on BMI for rs17782313 (0.25
TABLE 2
Continued
n (men/women) Genotype
Minor allele
frequency
Additive model
OR P
Waist
80 (women) or
94 cm (men) 5,293 (2,798/2,495) 2,192 (41) 2,391 (45) 710 (13) 36.0 (35.1–36.9)
80 (women) or
94 cm (men) 9,477 (4,961/4,516) 3,700 (39) 4,484 (47) 1,239 (14) 37.3 (36.6–38.0) 1.06 (1.01–1.12) 0.03
88 (women) or
102 cm (men) 5,692 (2,701/2,991) 2,209 (39) 2,709 (47) 774 (14) 37.4 (36.5–38.3) 1.05 (1.00–1.12) 0.07
Data are n (%), minor allele frequency (95% CI), and OR (95% CI). Differences in genotype distribution between BMI classifications or waist
circumference classifications were calculated applying an additive logistic regression model adjusted for sex and age. *P values remained
significant after Benjamini-Hochberg correction.
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kg/m2) and rs17700633 (0.23 kg/m2) were slightly larger
than the previous findings (0.22 and 0.15 kg/m2, respec-
tively [13]), whereas individuals homozygous for the minor
allele of rs12970134 had a 1.7 cm increased waist cir-
cumference, which was slightly lower than the previous
findings (2 cm [ref. 14]). ORs for overweight/obesity
(1.09) and obesity (1.12) defined by BMI for rs17782313
(Table 2) were comparable with previous findings (1.08
and 1.12, respectively) (13), whereas the effect on morbid
obesity (1.20) was less pronounced in the Danish popula-
tion than in the previously reported morbid obesity case-
control study (1.31) (13). This association was only
borderline significant in the Danish population; however, this
was probably due to a limited sample size (nmorbid-obese 
283), and the less pronounced effect in the Danish population
is likely due to a lower mean BMI in the Danish morbidly
obese case individuals. Naturally, rs12970134 was also asso-
ciated with overweight, obesity, and morbid obesity in the
Danish population, as this variant was in high linkage dis-
equilibrium with rs17782313 (r2  0.76 in the Danish Inter99
population). A novel association betweenmorbid obesity and
the A-allele of rs17700633 was identified, suggesting a more
pronounced effect on extreme obesity of this variant. Case-
control studies of sex-specific waist circumference, a surro-
gate measure of abdominal obesity, showed ORs comparable
with our studies of BMI-defined obesity.
In population-based studies of obesity-related quantita-
tive traits, rs17782313, rs17700633, and rs12970134 were
associated with waist circumference. However, adjust-
ment for BMI abolished these associations, which may
indicate an effect on global rather than abdominal obesity;
this effect may be further supported by the fact that waist
circumference, but not waist-to-hip ratio, was associated
with these variants. Furthermore, in agreement with pre-
vious findings, rs17782313 was positively associated with
height (13), pointing toward an influence on overall body
size for this variant. A possible association of rs12970134,
rs477181, rs502933, or rs4450508 with waist-to-hip ratio
(except rs12970134) and insulin resistance (HOMA-IR)
(14) was not replicated in the Danish population-based
study sample; likewise, associations of rs477181, rs502933,
and rs4450508 with BMI, waist circumference, or body
weight were also not replicated. A difference in ethnicity
may possibly explain the divergent results because only
38% of the individuals in the publication by Chambers et
al. (14) were of European ancestry, whereas62% were of
Indian Asian ancestry.
Conditional analyses of BMI as a quantitative trait
showed that the BMI effects of rs17782313 and rs17700633
were dependent on the BMI effect of rs12970134. A likely
explanation is that rs12970134 is in higher linkage disequi-
librium with the causal variant than rs17782313 and
rs17700633. However, in conditional analyses of case-
control studies of BMI, both rs12970134 and rs17700633
had independent effects. Therefore, we cannot exclude an
independent effect of rs17700633 on obesity, and this
suggests that rs17700633, located in a linkage disequilib-
rium block adjacent to rs12970134 and rs17782313, may
represent a different variant associated with obesity.
Because obesity is a predisposing factor for type 2
diabetes, we investigated a possible relationship between
the six variants near MC4R and type 2 diabetes. We
identified borderline significant associations for the obesi-
ty-associated risk alleles of rs17782313 and rs12970134
with type 2 diabetes (OR 1.08 for both variants), whereas
potential associations with type 2 diabetes did not reachTA
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statistical significance for the other four variants near
MC4R. The potential associations of rs17782313 and
rs12970134 with type 2 diabetes were abolished when
adjusting for BMI, indicating that a diabetogenic effect
might be mediated through an increase in BMI, analogous
to the association of variation in FTO with type 2 diabetes
(10,20). The increased risk of type 2 diabetes via obesity is
presumably through insulin resistance, although no differ-
ence in HOMA-IR (regardless of correction for BMI) was
found between individuals with or without the risk alleles.
We estimated statistical power to detect the expected
effect of variants near MC4R on HOMA-IR based on the
MC4R effect on BMI and the correlation between BMI and
HOMA-IR, and we found a statistical power below 50% for
all variants. Therefore, the lack of association of variants
near MC4R with HOMA-IR may be due to low statistical
power in the present study.
The present study demonstrated an additive effect be-
tween rs12970134 near MC4R and FTO rs9939609 on BMI
(Fig. 1A and B). The FTO rs9939609 had the largest effect;
however, rs12970134 near MC4R contributed to this asso-
ciation on top of rs9939609.
It is still unsettled which variants in the genomic region
are causal. Loos et al. (13) showed that the associations
with obesity were not secondary to an association be-
tween the MC4R Val103Ile polymorphism and lower risk
of obesity (13). Given that rs17782313, rs12970134, and
rs17700633 are located between 188 and 109 kb down-
stream of MC4R, it is also unknown whether the causal
variants actually influence regulation of MC4R, although
this is the most likely biological candidate gene in the
region, as the pattern of phenotypic association is consis-
tent with an effect mediated through altered MC4R func-
tion. Therefore, variants mapping far away from adjacent
coding sequences may modulate phenotypes through re-
mote effects on expression or translation.
In summary, we have extended the present knowledge
of rs17782313, rs17700633, and rs12970134 near MC4R and
validated that the variants associate with various mea-
sures of obesity in the Danish population. These variants
may only be markers in linkage disequilibrium with the
causal variants, and future studies identifying functional
evidence linking rs17782313, rs17700633, and rs12970134
to expression of MC4R or another obesity-related gene are
needed.
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